ORALS

SESSION: MedicineTuePM2-R1	Intl. Symp. on Technological Innovations in Medicine for Sustainable Development
Tue. 29 Nov. 2022 / Room: Ballroom B
Session Chairs: Osamu Kimura; Session Monitor: TBA

15:55: [MedicineTuePM209] OS Plenary
Non-invasive cancer therapy with the latest medical technologies and a new treatment concept
Shinichi Hori¹ ; Atsushi Hori¹ ; Tatsuya Nakamura¹ ; ¹Institute for Image Guided Therapy, Izumisano, Japan;
Paper Id: 460 [Abstract]

Over the past decade, cancer treatment has made remarkable progress. The standard treatments-surgery, radiotherapy, and systemic chemotherapy have played a significant role. Nevertheless, standard treatments continue to cause side effects for a growing number of patients. Further complicating matters, cancer treatment is becoming increasingly expensive. The solutions to these problems require the application of some new concepts and newly developed medical technologies[1]. Cancer treatment with less damage to patients, enabling patients to carry on with their work as well as normal family lives even after treatment should never be defined as a miracle cure but as a practical treatment. Nowadays, with the help of the latest medical imaging technology, it is feasible to identify the exact location of cancer and find the best approach to treatment[2]. Then a microcatheter with a diameter as small as 0.7 mm can be inserted into a patient’s body and travel anywhere in the body[3]. Additionally, the spherical embolic microspheres deliver drugs for an extended period while keeping the drugs remaining inside the targeted lesion[4]. With these technologies, we continue to develop new methods of cancer treatment. Moreover, if cancer treatment were aimed at living with cancer in a non-life-threatening situation rather than eradicating it, cancer treatment would be significantly changed. There are very few cancer patients who have benefited from "arterial embolization," which is only known to a small number of medical experts. Our team has been working on this treatment for 20 years, and we are still trying to find ways to achieve better treatment outcomes while also reducing medical costs, and allowing more people to live cancer-free. The purpose of this presentation is to demonstrate how this treatment is applied to patients and what kind of therapeutic effect it has. This medical technology will play a crucial role in the effective delivery of new drugs to the targeted lesion, as well as in the fields of immunotherapy and regenerative medicine.

References:
[1] S. Hori, T. Nakamura, N. Kennoki, I. Dejima, and A. Hori, “Transarterial management of advance lung cancer,” Jpn. J. Clin. Oncol., vol. 51, no. 6, pp. 851–856, May 2021, doi: 10.1093/jjco/hyab050.
[2] T. Tanaka et al., “Current role of hybrid CT/angiography system compared with C-arm cone beam CT for interventional oncology,” Br. J. Radiol., vol. 87, no. 1041, p. 20140126, Sep. 2014, doi: 10.1259/bjr.20140126.
[3] Z. Wang et al., “Superselective arterial embolization with drug-loaded microspheres for the treatment of unresectable breast cancer,” Gland Surg., vol. 8, no. 6, pp. 740–747, Dec. 2019, doi: 10.21037/gs.2019.12.06.
[4] N. Kennoki, S. Hori, T. Yuki, and A. Hori, “Transcatheter Arterial Chemoembolization with Spherical Embolic Agent in Patients with Pulmonary or Mediastinal Metastases from Breast Cancer,” J. Vasc. Interv. Radiol., vol. 28, no. 10, pp. 1386–1394, Oct. 2017, doi: 10.1016/j.jvir.2017.06.003.